ENZON PHARMACEUTICALS
About Enzon
Technology Platforms
Research & Development
Marketed Products
Partnering
Newsroom
Investors
Careers
Contact Us
Search
»
Enzon transforms possibilities into realities

ENZON COMPLETES SALE OF SPECIALTY PHARMACEUTICAL BUSINESS

Enzon Pharmaceuticals, Inc. has closed the sale of its specialty pharmaceutical business to sigma-tau. The specialty pharmaceutical business sold includes four marketed products, Abelcet® (amphotericin B lipid complex injection), Adagen® (pegademase bovine), Depocyt® (cytarabine liposome injection), and Oncaspar® (pegaspargase), as well as the manufacturing facility in Indianapolis, Indiana. In the future, please refer to www.sigmatau.com for information regarding these products and services.

Enzon is continuing to assist sigma-tau in supporting these products for a limited time. Enzon’s Medical Information hotline (866-792-5172) and Drug Safety hotline (800-836-4301) are available to receive questions or adverse event reports.

Enzon News
01/29/2010
Enzon Completes Sale of Specialty Pharmaceutical Business MORE
01/27/2010
Enzon Stockholders Approve Sale of Specialty Pharmaceutical Business MORE
Stock Information
(ENZN) NASDAQ
Last Trade9.00
Change(%)price0.00
Volume0
4:12 AM - Feb 09, 2010
Investor Relations
Annual Report
The 2008 Enzon annual report is available to read online.
MORE
Mailing List
Enter your email address to sign up for the Enzon mailing list.

 
Copyright © 2005-2008 Enzon Pharmaceuticals, Inc. All rights reserved.
Terms of Use